Abstract: A superconductor junction includes a normal metal layer having a first side and a second side, an insulating layer overlying the second side of the normal metal layer, and a first superconductor layer formed of a first superconductor material that overlies a side of the insulating layer opposite the side that overlies the normal metal layer. The superconductor junction further includes a second superconductor layer formed of a second superconductor material with a first side overlying a side of the first superconductor material opposite the side that overlies the insulating layer. The second superconductor material has a higher diffusion coefficient than the first superconductor material and/or the second superconductor material has a lower recombination coefficient than the first superconductor metal layer. A normal metal layer quasiparticle trap is coupled to a second side of the second superconductor layer.

Abstract: An automated avocado processing system for cutting an avocado in half, removing the pit, and extracting the flesh from the peel includes a plurality of functional assemblies arranged on a frame. Exemplary stations include a loading assembly, cutting assembly, peeling station, and food collection assembly. Computer and electronics are programmed and operable to control the automated stations. Related methods are described.

Abstract: A highly stable cannabinoid nanoparticle carrier composition for administration to a human made by incorporating non-ionic surfactants with cannabinoid oils and lipids, sonicating for a predetermined period of time at a predetermined amplification with an ultrasonic liquid processor until completely integrated; combining the mixture with a carrier fluid that includes ascorbic acid and distilled water; and further sonicating the mixture using an ultrasonic liquid processor at predetermined amplitude for a predetermined period of time at a controlled temperature, and thereby to create a CBD nanoemulsion. The composition is tailored using non-ionic surfactants to adsorb to the surface of the cannabinoid oil particles to advantageously affect electrokinetics and surface forces at the interface of the bioactive cannabinoid particles and the suspending liquid are controlled by tailoring the suspending liquid to maximize the zeta potential.

Abstract: A method of producing a cannabinoid nanoparticle carrier composition for administration to a human, including the steps of incorporating non-ionic surfactants with cannabinoid oils and lipids; inducing sonication for a predetermined period of time at a predetermined amplification with a ultrasonic liquid processor until completely integrated; dissolving ascorbic acid into a carrier fluid; combining in sequence the non-ionic surfactants, lipids, and cannabinoids with a carrier fluid consisting of distilled water and ascorbic acid; sonicating using an ultrasonic liquid processor at predetermined amplitude for a predetermined period of time at a controlled temperature.

Abstract: An anorectal expulsion device includes a balloon having a wall that extends between proximal and distal ends of the balloon and defines a balloon interior. The balloon interior contains a self-expanding, low compression-set material (e.g., open cell foam). The device also includes a catheter that extends through the proximal end of the balloon and at least a portion of the balloon interior. An interior of the catheter is in fluid communication with the balloon interior. The device also includes a termination component (e.g., a cap or a valve) coupled to the catheter at a position along the catheter that is outside of and proximal to the proximal end of the balloon (e.g., at the proximal end of the catheter). The physical configuration of the termination component is adjustable, and controls whether the balloon interior is in fluid communication with the external environment.

Abstract: A method of producing a cannabinoid nanoparticle carrier composition for administration to a human and thereafter producing a consumable food product including the cannabinoid nanoparticle emulsification.

Abstract: A method of producing a cannabinoid nanoparticle carrier composition for administration to a human, including the steps of incorporating non-ionic surfactants with cannabinoid oils and lipids; inducing sonication for a predetermined period of time at a predetermined amplification with a ultrasonic liquid processor until completely integrated; dissolving ascorbic acid into a carrier fluid; combining in sequence the non-ionic surfactants, lipids, and cannabinoids with a carrier fluid consisting of distilled water and ascorbic acid; sonicating using an ultrasonic liquid processor at predetermined amplitude for a predetermined period of time at a controlled temperature.

Abstract: Disclosed is an apparatus and system for cleaning paint rollers. The apparatus may include a container with a top portion, bottom portion, and one or more side portions; wherein the top portion may have a delivery slot formed therethrough to facilitate the delivery of liquid from an exterior environment to the interior of the container. A securing slot may be formed at the intersection between the top portion and the one or more side portions to facilitate the securing of a paint roller within the container. One or more drainage pipes may be disposed on the one or more side portions or the bottom portion to facilitate liquid waste draining from an interior environment to the exterior.

Abstract: A vaccine for human hookworm is provided. The vaccine comprises at least one L3 larval stage antigen (e.g. Na-ASP-2 or Na-SAA-2) and at least one adult stage human hookworm antigen (e.g. Na-APR-1, Na-CP-2, Na-CP-3, Na-CP-4, Na-CP-5, or Na-GST-1) and adjuvants.

Abstract: A vaccine for human hookworm is provided. The vaccine comprises at least one L3 larval stage antigen (e.g. Na-ASP-2 or Na-SAA-2) and at least one adult stage human hookworm antigen (e.g. Na-APR-1, Na-CP-2, Na-CP-3, Na-CP-4, Na-CP-5, or Na-GST-1) and adjuvants.

Abstract: A vaccine for human hookworm is provided. The vaccine comprises at least one L3 larval stage antigen (e.g. Na-ASP-2 or Na-SAA-2) and at least one adult stage human hookworm antigen (e.g. Na-APR-1, Na-CP-2, Na-CP-3, Na-CP-4, Na-CP-5, or Na-GST-1) and adjuvants.